PeptidePedia The community reference

List of GLP-1 receptor agonists (revision 2)

Old revision·13:35, 11 Aug 2024·RetinopathyRex

This is an old revision of this page, as it stood at 13:35, 11 Aug 2024, saved by RetinopathyRex with the summary state plainly what this list does not cover. It may differ substantially from the current revision, and any error it contains may since have been corrected.
List of GLP-1 receptor agonists
ScopeAgonists at the GLP-1 receptor, alone or with others
ExcludedDPP-4 inhibitors, which raise endogenous hormone
List infobox · conventions

This list enumerates agonists at the GLP-1 receptor, including those that also engage other receptors of the glucagon-secretin family. DPP-4 inhibitors are excluded: they raise endogenous incretin concentrations rather than agonising the receptor directly. See Dipeptidyl peptidase-4.[1]

Status is given as approved or investigational without specifying jurisdiction, since approval differs between countries. See Regulatory status by jurisdiction.[2]

GLP-1 receptor agonists

[edit]
CompoundRouteIntervalStatus
ExenatideSubcutaneousTwice daily or weeklyApproved
LixisenatideSubcutaneousDailyApproved
LiraglutideSubcutaneousDailyApproved
DulaglutideSubcutaneousWeeklyApproved
SemaglutideSubcutaneousWeeklyApproved
Oral semaglutideOralDailyApproved
OrforglipronOralDailyInvestigational

The list spans three architectures: exendin-derived peptides, acylated GLP-1 analogues, an Fc fusion, and a non-peptide small molecule. See GLP-1 receptor agonist for how each solves the half-life problem.[1]

References

  1. ^ a b Drucker DJ. "Mechanisms of action and therapeutic application of glucagon-like peptide-1." Cell Metabolism 27(4):740–756 (2018). PMID 29617641.
  2. ^ American Diabetes Association. "Standards of Care in Diabetes." Diabetes Care 47(Suppl 1) (2024).
Categories: